Treats asthma. ANDA 213471, held by Aurobindo Pharma. Montelukast Sodium.
As of Nov 21, 2026, ANDA 213471 (Montelukast Sodium), held by Aurobindo Pharma, was first approved by FDA on Feb 18, 2020, with 2 approved supplements and 0 published complete response letters.
Montelukast sodium is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 12 months of age and older. Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies. Limitations of Use: Not indicated to treat an acute asthma attack. 1.1 Asthma Montelukast sodium oral granules are indicated for the prophylaxis and chronic treatment of asthma in pediatric patients 12 months of age and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 18, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Montelukast SodiumEQ 4MG BASE/PACKET · granule;oral | Montelukast Sodium | Rx |
| Jul 30, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 30, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 18, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters